HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mucositis

An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
Also Known As:
Mucositides
Networked: 4549 relevant articles (458 outcomes, 804 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Pain (Aches)
3. Head and Neck Neoplasms (Head and Neck Cancer)
4. Peri-Implantitis
5. Stomatitis

Experts

1. Gibson, Rachel J: 42 articles (11/2015 - 07/2002)
2. Howarth, Gordon S: 41 articles (01/2020 - 05/2003)
3. Sonis, Stephen T: 39 articles (01/2021 - 01/2002)
4. Bowen, Joanne M: 35 articles (12/2017 - 09/2005)
5. Stringer, Andrea M: 30 articles (01/2020 - 01/2007)
6. Keefe, Dorothy M K: 29 articles (09/2011 - 07/2002)
7. Epstein, Joel B: 27 articles (03/2022 - 07/2002)
8. Lalla, Rajesh V: 24 articles (10/2020 - 06/2006)
9. Logan, Richard M: 23 articles (11/2022 - 01/2007)
10. Butler, Ross N: 22 articles (12/2019 - 05/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mucositis:
1. Fluorouracil (Carac)FDA LinkGeneric
2. Amifostine (Ethyol)FDA LinkGeneric
3. ChlorhexidineIBA
4. Glutamine (L-Glutamine)FDA Link
5. Irinotecan (Camptosar)FDA LinkGeneric
6. CytokinesIBA
7. Methotrexate (Mexate)FDA LinkGeneric
8. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
9. Cisplatin (Platino)FDA LinkGeneric
10. MouthwashesIBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Therapeutics
01/01/2008 - "The pathobiology of alimentary mucositis is extremely complex, and an increased understanding of mechanisms and pathway interactions is required to rationally design improved therapies. "
06/03/2015 - "The main meta-analyses showed that IDA compared with DNR prolonged overall survival (OS) (12 studies, 5976 patients; HR 0.90, 95% confidence interval (CI) 0.84 to 0.96, P = 0.0008; high quality of evidence) and disease-free survival (DFS) (eight studies, 3070 patients; HR 0.88, 95% CI 0.81 to 0.96, P = 0.004; moderate quality of evidence), increased complete remission (CR) rate (18 studies, 6692 patients; RR 1.04, 95% CI 1.01 to 1.07, P = 0.009; moderate quality of evidence), and reduced relapse rate (four studies, 1091 patients; RR 0.88, 95% CI 0.80 to 0.98, P = 0.02; moderate quality of evidence), although increased the risks of death on induction therapy (14 studies, 6349 patients; RR 1.18, 95% CI 1.01 to 1.36, P = 0.03; moderate quality of evidence) and grade 3/4 mucositis (five studies, 2000 patients; RR 1.22, 95% CI 1.04 to 1.44, P = 0.02; moderate quality of evidence). "
01/01/2022 - "Clinical parameters related to peri-implant mucositis significantly improved in the Study Group, which demonstrated the clinical efficacy of the Bioptron Hyperlight Therapy as an adjunct to standard of care for the treatment of peri-implant mucositis. "
01/01/2022 - "Bacillus clausii UBBC07 therapy delayed the onset, decreased the time to remission and displayed strong impact on suppressing the occurrence of high-grade mucositis amongst the test group. "
11/01/2015 - "Despite the significant impact of mucositis, there are currently limited clinically effective pharmacological therapies for the pathology. "
3. Radiotherapy
4. Debridement
5. Chemoradiotherapy